Suven Life Sciences Ltd announced on May 13, 2025, that its board approved a preferential issuance of up to 6,40,02,999 convertible equity warrants at ₹134 each, totaling up to ₹857.64 crores, subject to shareholder approval.
AI Assistant
Suven Life Sciences Ltd
2025
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.